Gesynta Pharma randomized 50% of patients in its Phase 2 endometriosis trial of vipoglanstat.
Gesynta Pharma is a clinical stage pharmaceutical company developing innovative treatments by targeting mPGES-1, an important pro-inflammatory enzyme with a key role in endometriosis
Gesynta Pharma is a clinical stage pharmaceutical company developing innovative treatments by targeting mPGES-1, an important pro-inflammatory enzyme with a key role in endometriosis. The company's leading compound, vipoglanstat, is a selective mPGES-1 inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential.